Contact This Organization

Invenio Genetics

Invenio Genetics, launched in 2019, is the 18th member-founded joint venture of the Innovation Institute. Building on the success of Avera’s Institute for Human Genetics’ pharmacogenomic and nutrigenomic programs, Invenio Genetics works with member and non-member healthcare providers to launch genetic and genomic testing.
To cultivate innovative solutions in collaboration with others, transforming healthcare by doing more, with less, for more people.
Type of Organization
Startup - Newly established businesses, investable
Size of Organization
Organization Mailing Address

1 Centerpointe Drive
Suite 200
La Palma, CA 90623
United States

Medication Analysis (Multigene Pharmacogenomics Panel)
Invenio's Medication Analysis is a DNA test that looks at key genes that can affect how your body processes dozens of medications used to treat a variety of medical conditions. The results may help you and your doctor make informed decisions about which medication may be optimal for you.
Category of Innovation
Digital Health - A digital health solution is a technology-based solution whose user is caring for or providing care for themselves (think of a personal app) or another individual (such as a doctor using a tool to help their patient)
Intended End User
Patient - Individuals who receive health care
Provider - Individuals or organizations responsible for providing care to patients (e.g. doctors, nurses, hospital/clinic administrators, etc.)
Payer - Organizations responsible for issuing or administering payment for the care received by a population of people (e.g. insurance companies)
Purchaser - Organizations responsible for purchasing health benefits for a population of people (e.g. employers or government entities)
Impactful Innovation Stage (Click Here for Details)
Problem (i.e. barrier, issue, complication, etc.) being solved for the end user
- ONLY 10% of PCPs are comfortable with PGx: further education and automation needed to enable PGx growth.
- ALL individuals carry actionable variants: 9 of 10 patients hospitalized with COVID-19 need multigene PGx.
- 37M Americans take antidepressants, with 50% of diagnosed patients NOT RESPONDING to 1st medication.
- PGx tested patients with Major Depressive Disorders were 71% MORE LIKELY to recover on their medication regimen.
Idea/solution to the problem, if applicable
The way your body responds to medications depends on many factors, including your DNA. For example, if you have never taken a medication for anxiety or depression, you and your doctor can use the results of the Invenio's Medication Analysis test to assist in determining which medication to start first. Or, if a medication did not work well for you in the past or you experienced side effects, your doctor may consider your DNA results along with other health factors to adjust the dose or choose a different medication that’s better suited for you.
Level of adoption (i.e. list of customers/users, testimonials, etc.), if applicable
Invenio's Medication Analysis is currently utilized within 2 large Midwest IDNs.
Funding Stage
Not Applicable
College of American Pathologists (CAP) accreditation, Clinical Laboratory Improvement Amendments (CLIA) certification, and Propel Certified Service Provider through Illumina.
Has your company attested to any codes of conduct?
Genetic Information Nondiscrimination Act (GINA)